Eli Lilly and Company (Symbol:LLY) SWOT Analysis, Strategy, Revenues and Profits

• Publication date: April 2013
• Report size: 66 pages

Eli Lilly and Company (Lilly) is a pharmaceutical company, which is principally engaged in the design, development, manufacture, and selling of pharmaceutical products by utilizing up-to-date technological tools. It also conducts research to discover products to treat disease in animals. The company owns over 130 subsidiaries operating throughout the world. Lilly’s product portfolio includes Neuroscience products, Endocrinology products...

Eli Lilly and Company (Lilly) is a pharmaceutical company, which is principally engaged in the design, development, manufacture, and selling of pharmaceutical products by utilizing up-to-date technological tools. It also conducts research to discover products to treat disease in animals. The company owns over 130 subsidiaries operating throughout the world. Lilly’s product portfolio includes Neuroscience products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products and Other pharmaceuticals. Its products are marketed in more than 143 countries worldwide. The company is headquartered in Indiana, the US

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.

Eli Lilly and Company SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.

In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods

You get also in deepth information about Eli Lilly and Company operations to identify potential customers, partners and suppliers. Eli Lilly and Company business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.



Latest Company Developments:

Global Pathology Industry

I - Eli Lilly and Company Company Profile

Key Information
Overview
Key Employees and biographies
Operational Heads
Main Products and Services
Historical Data
Company Mission Statement
Operations And Subsidiaries
Headquarter

II - Eli Lilly and Company Company Analysis

Business Description
Company Vision and Strategy
SWOT Analysis
Strengths, Weaknesses, Opportunities, Threats
Competitive Landscape

III - Eli Lilly and Company Financial Analysis and Performance Charts

Financial Ratios
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios

Cancer in World

Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Iraq, World

Cook Islands Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Togo Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Togo, World

Micronesia( Federated States Of) Prostate Cancer, 60-69 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cuba Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Cuba, World

Pathology in World

Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cote D`ivoire Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Congo-brazzaville Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Mali Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Mali, World

Trinidad & Tobago Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World